Mifepristone is a medicine that blocks the action of progesterone, a hormone needed to maintain pregnancy. For medical termination of an early intrauterine pregnancy, mifepristone is used together with another prescription medicine called misoprostol.
According to FDA-approved prescribing information, mifepristone 200mg is indicated, in combination with misoprostol, for medical termination of an intrauterine pregnancy through 70 days (10 weeks) of gestation.
Mifepristone should not be considered a standalone medicine for this indication. The approved regimen includes misoprostol and requires appropriate patient assessment and follow-up.
The pregnancy commonly passes with bleeding and cramping, which may be heavier than a normal menstrual period.
Mifepristone blocks progesterone receptors.
Progesterone is important for maintaining the uterine lining during pregnancy. By blocking progesterone activity, mifepristone helps prepare the uterus for the subsequent action of misoprostol.
Misoprostol causes uterine contractions, helping the pregnancy pass from the uterus. The FDA medication guide states that the pregnancy is likely to pass within approximately 2–24 hours after taking mifepristone and misoprostol, although individual experiences can vary.
Mifepristone for medical termination may be appropriate for an eligible person with an early intrauterine pregnancy, when assessed by an appropriate healthcare professional.
The FDA-approved regimen is for pregnancy up to 70 days (10 weeks) from the first day of the last menstrual period.
Before treatment, the healthcare provider may assess:
Mifepristone should not be used for medical termination when certain contraindications are present.
These include:
An IUD must be removed before using mifepristone for this indication.
Mifepristone should be used according to a qualified healthcare professional's instructions.
For the FDA-approved regimen, the prescribing information specifies:
Day 1: Mifepristone 200mg orally
24–48 hours later: Misoprostol 800 micrograms, administered according to the approved regimen.
Follow-up is required to confirm that the pregnancy has been completely terminated.
Do not substitute a different dose, timing schedule or medication combination without medical guidance.
Mifepristone is a prescription medicine and should be used after consultation with a qualified healthcare professional.
A healthcare professional should determine whether the medicine is appropriate, particularly because an ectopic pregnancy must be excluded and certain medical conditions can make treatment unsafe.
The healthcare provider should also explain expected bleeding/cramping, possible complications, follow-up requirements and what to do in an emergency.
After the mifepristone/misoprostol regimen, patients commonly experience:
Bleeding and cramping can be heavier than during a usual menstrual period.
Heavy or prolonged bleeding can indicate incomplete pregnancy termination or another complication and may require medical or surgical treatment.
Serious infection and severe bleeding are rare but potentially serious complications. Seek urgent medical care for symptoms such as:
The FDA prescribing information specifically warns about serious infection and bleeding and emphasizes prompt medical assessment when concerning symptoms occur.
Mifepristone 200mg is used with misoprostol for medical termination of an early intrauterine pregnancy through 70 days (10 weeks) under the FDA-approved regimen.
No. They are different medicines with different actions. Mifepristone blocks progesterone, while misoprostol causes uterine contractions and helps the pregnancy pass.
For the medical termination indication described here, mifepristone is used as part of a regimen with misoprostol.
The FDA prescribing information specifies 200mg of mifepristone on Day 1, followed 24–48 hours later by 800 micrograms of misoprostol.
After mifepristone and misoprostol, the pregnancy is likely to pass within approximately 2–24 hours, although the timing varies between individuals.
Yes. Bleeding and cramping are expected effects of the treatment regimen and may be heavier than a normal period.
No. Mifepristone used for medical termination is contraindicated when an ectopic pregnancy is confirmed or suspected.
The FDA-approved information states that an IUD must be removed before mifepristone is used for this indication.
Mifepristone is considered safe and effective when used for its approved indication and according to appropriate medical guidance. However, serious complications such as severe bleeding or infection can rarely occur.
Yes. Follow-up is needed to confirm that the pregnancy has been completely terminated.
People with ectopic pregnancy, certain adrenal conditions, certain bleeding disorders, anticoagulant use, inherited porphyria, relevant allergies, an IUD still in place, or other listed contraindications should not use it without appropriate medical assessment.
The FDA-approved medical-termination regimen described here is for an intrauterine pregnancy through 70 days (10 weeks). Treatment outside that indication requires appropriate specialist medical assessment.
Product original packing mein mila